Sevorane: Uses, Dosage & Side Effects

What Is Sevorane and What Is It Used For?

Sevorane contains the active substance sevoflurane, a volatile halogenated ether that belongs to the class of general inhalation anesthetics. It is a clear, colorless liquid with a mild, pleasant odor that is converted into a vapor by a specialized device called a vaporizer. The anesthesiologist controls the concentration of sevoflurane vapor in the breathing gas mixture to achieve and maintain the desired depth of anesthesia throughout the surgical procedure.

Sevoflurane was first synthesized in the 1960s and introduced into clinical practice in the 1990s. It quickly became one of the most widely used volatile anesthetics in the world due to several pharmacological advantages over older agents such as halothane and isoflurane. Its low blood-gas partition coefficient of 0.63–0.69 means that sevoflurane is rapidly taken up from the lungs into the bloodstream and equally rapidly eliminated when the administration is stopped. This translates to fast induction of anesthesia (typically within 1–2 minutes of mask induction) and quick emergence and recovery after surgery.

Unlike some other volatile anesthetics, sevoflurane has a pleasant, non-pungent odor and does not irritate the airways. These properties are particularly valuable during mask induction of anesthesia, where the patient breathes the anesthetic vapor through a face mask rather than receiving an intravenous injection first. Mask induction is commonly used in children, who may find the placement of an intravenous line distressing, and in adults who prefer not to have an initial injection. The smooth, non-irritating characteristics of sevoflurane minimize the risk of coughing, breath-holding, laryngospasm, and excessive salivation during induction.

Sevoflurane produces general anesthesia through multiple mechanisms of action in the central nervous system. It enhances the activity of inhibitory gamma-aminobutyric acid type A (GABA-A) receptors and glycine receptors, while simultaneously inhibiting excitatory N-methyl-D-aspartate (NMDA) receptors and nicotinic acetylcholine receptors. The net effect of these actions is a dose-dependent depression of central nervous system function, producing the key components of general anesthesia: unconsciousness, amnesia (no memory of the procedure), analgesia (reduced pain perception), and immobility in response to surgical stimulation.

Sevorane is listed on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its importance as a fundamental tool in modern surgical practice. It is approved by regulatory agencies worldwide, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), under various brand names including Sevorane (in Europe and many other countries) and Ultane (in the United States). The medication is used exclusively by qualified anesthesiologists and trained healthcare professionals in hospital operating rooms, ambulatory surgery centers, and other approved clinical settings.

What Should You Know Before Receiving Sevorane?

Contraindications

There are specific situations in which Sevorane must not be administered. Understanding these absolute contraindications is essential for safe anesthetic practice, and your anesthesiologist will carefully screen for these before any procedure.

• Malignant hyperthermia susceptibility: Sevorane is absolutely contraindicated in patients with a known or suspected genetic susceptibility to malignant hyperthermia (MH). MH is a rare but potentially fatal pharmacogenetic disorder in which exposure to volatile anesthetics triggers uncontrolled skeletal muscle hypermetabolism, leading to rapidly rising body temperature, muscle rigidity, metabolic acidosis, and potentially cardiac arrest. If you have a personal or family history of MH, inform your anesthesiologist immediately.
• Hypersensitivity to halogenated anesthetics: Do not receive Sevorane if you have previously experienced a serious adverse reaction during or after anesthesia with a halogenated anesthetic agent (such as sevoflurane, isoflurane, desflurane, or halothane). This includes unexplained liver damage (hepatitis, jaundice, liver necrosis), unexplained fever, or elevated eosinophil counts following previous halogenated anesthetic exposure.

Warnings and Precautions

Before and during anesthesia with Sevorane, your anesthesiologist should be informed if any of the following conditions apply to you:

• Low blood pressure or dehydration: Sevoflurane causes dose-dependent decreases in blood pressure. Patients who are hypotensive, dehydrated, or hypovolemic are at increased risk of significant hemodynamic depression and should be carefully resuscitated before induction of anesthesia.
• Kidney disease: Sevoflurane is metabolized to inorganic fluoride, and when it reacts with carbon dioxide absorbents (particularly barium hydroxide lime), it can produce a nephrotoxic compound known as Compound A. While clinical studies in humans have not demonstrated significant renal toxicity at recommended flow rates, patients with pre-existing renal impairment require careful monitoring. Minimum fresh gas flow rates of 2 L/min for procedures exceeding 2 hours are generally recommended.
• Heart conditions or arrhythmias: Sevoflurane can cause QT prolongation and may sensitize the myocardium to the arrhythmogenic effects of catecholamines, though to a lesser extent than older agents like halothane. Patients with pre-existing cardiac conduction abnormalities, coronary artery disease, or those taking medications that affect cardiac rhythm should be monitored closely.
• Seizure disorders: Sevoflurane has been associated with electroencephalographic (EEG) changes and, rarely, clinical seizure activity, particularly at higher concentrations and during rapid increases in inspired concentration. Patients with a history of epilepsy or seizure disorders may be at increased risk and should be managed accordingly.
• Liver disease: Rare cases of hepatotoxicity, including hepatic necrosis and hepatic failure, have been reported following sevoflurane anesthesia. If you have experienced liver damage, jaundice, fever, or elevated eosinophils after previous halogenated anesthetic exposure, an alternative non-halogenated anesthetic technique should be used. Repeated exposures to halogenated anesthetics within a short time interval may increase the risk of hepatic injury.
• Neuromuscular disorders: Patients with neuromuscular conditions, particularly Duchenne muscular dystrophy and Pompe disease, are at increased risk for serious adverse events during sevoflurane anesthesia, including cardiac arrhythmias, rhabdomyolysis, hyperkalemia, and cardiac arrest. The use of succinylcholine in these patients further elevates the risk.
• Mitochondrial disorders: Patients with mitochondrial diseases may be particularly sensitive to the effects of volatile anesthetics. Special precautions and careful monitoring are recommended in these individuals.
• Raised intracranial pressure: Sevoflurane, like other volatile anesthetics, can increase cerebral blood flow and intracranial pressure at concentrations above 1.5 MAC. In patients with raised intracranial pressure or at risk of cerebral edema, careful titration of the anesthetic depth and additional measures to control intracranial pressure may be required.

As with all general anesthetics, mild changes in mood, cognition, and psychomotor function may persist for several days following anesthesia with sevoflurane. These changes are typically subtle and resolve completely within 24–72 hours. However, patients should be informed that their alertness and judgment may be impaired during this period.

Pregnancy and Breastfeeding

Pregnancy: There is limited clinical experience with sevoflurane use during pregnancy. Animal studies have not demonstrated teratogenic effects, but sevoflurane crosses the placenta and can cause neonatal respiratory depression. Sevorane should be used during pregnancy only when the clinical benefit clearly outweighs the potential risk to the fetus, and only after careful consideration by the treating physician. Sevoflurane may be used for cesarean section deliveries when indicated, but the concentration and duration of exposure should be carefully minimized.

Breastfeeding: It is not known whether sevoflurane or its metabolites are excreted in human breast milk. Due to the lack of documented experience, mothers are advised to avoid breastfeeding for 48 hours after receiving sevoflurane anesthesia and to discard any breast milk produced during this period. Consult your physician if you have any concerns about breastfeeding after anesthesia.

Driving and Operating Machinery

Sevorane has a profound effect on your ability to drive and operate machinery. You must not drive, operate tools, or use machinery until your anesthesiologist has confirmed that it is safe to do so. General anesthetics can impair alertness, coordination, judgment, and reaction time for several days after the procedure. This means that activities requiring mental alertness should be avoided, and you should arrange for someone to drive you home after surgery. Your anesthesiologist will provide specific guidance on when it is safe to resume these activities.

How Does Sevorane Interact with Other Drugs?

Sevoflurane has clinically significant interactions with many medications commonly encountered in the perioperative setting. Your anesthesiologist will review your complete medication list and make appropriate adjustments to your anesthetic plan. The following interactions are the most important to be aware of.

Major Interactions

Other Notable Interactions

What Is the Correct Dosage of Sevorane?

Sevorane is used exclusively by qualified anesthesiologists and is never self-administered. The dosage is highly individualized and continuously adjusted throughout the surgical procedure based on the patient’s response, vital signs, and the requirements of the surgery. The primary measure of anesthetic potency for volatile agents is the minimum alveolar concentration (MAC), defined as the end-tidal concentration of the anesthetic that prevents movement in response to a surgical skin incision in 50% of patients.

Adults

Children

Elderly Patients

Overdose

Because Sevorane is administered under strict medical supervision with continuous monitoring of end-tidal concentration, vital signs, and depth of anesthesia, overdose in the traditional sense is unlikely. However, inadvertent overdosage can manifest as excessive depth of anesthesia with profound hypotension, severe bradycardia, respiratory depression, and cardiac arrest.

In the event of an overdose or excessively deep anesthesia, the anesthesiologist will immediately discontinue sevoflurane administration, ensure adequate ventilation with 100% oxygen, and provide supportive measures including intravenous fluids, vasopressors, and atropine as needed. Due to sevoflurane’s rapid elimination (low blood-gas partition coefficient), the depth of anesthesia decreases quickly once the agent is turned off, and most patients recover promptly with appropriate supportive care.

What Are the Side Effects of Sevorane?

Sevoflurane, like all volatile anesthetics, produces dose-dependent depression of cardiovascular and respiratory function. The majority of side effects are mild to moderate in severity and resolve spontaneously during the recovery period. Post-operative nausea and vomiting (PONV) and emergence delirium (particularly in children) are commonly reported after sevoflurane anesthesia, though these may also be influenced by other perioperative factors including the type of surgery, other medications administered, and individual patient characteristics.

It is important to distinguish between effects directly attributable to sevoflurane and those that are part of the normal postoperative course. Many symptoms such as nausea, pain, and confusion are common after any surgical procedure regardless of the anesthetic agent used.

If you experience any unexpected symptoms after receiving sevoflurane anesthesia, or if you develop yellowing of the skin or eyes (jaundice), unexplained fever, dark urine, or persistent nausea and vomiting in the days following your procedure, contact your healthcare provider promptly. While severe hepatic reactions are extremely rare, early detection is important for optimal management.

How Should Sevorane Be Stored?

Sevorane is supplied as a clear, colorless liquid in amber-colored plastic bottles of 250 mL. As a hospital-administered medication, patients do not need to store Sevorane at home. The medication is managed entirely by healthcare professionals within the hospital or surgical facility.

There are no special storage temperature requirements for Sevorane. However, it should be stored in its original container with the cap securely fastened to prevent evaporation and exposure. The bottles should be kept away from open flames and heat sources, as sevoflurane is a volatile organic compound. The medication should be stored out of reach of children and unauthorized personnel, in accordance with hospital pharmacy protocols for anesthetic agents.

Sevorane is filled into vaporizers using a dedicated filling system with a keyed adapter that is permanently integrated with the bottle. This closed filling system minimizes the risk of spillage, vapor exposure to healthcare workers, and accidental filling of the wrong vaporizer. Different vaporizer models, including the Aladin cassette system, are compatible with the Sevorane filling system. Healthcare professionals should follow their facility’s occupational health and safety guidelines for handling anesthetic gases, including ensuring adequate scavenging systems are in place in operating rooms.

What Does Sevorane Contain?

The formulation of Sevorane is remarkably simple, consisting of only two components:

• Active substance: Sevoflurane (fluoromethyl 2,2,2-trifluoro-1-[trifluoromethyl]ethyl ether). Sevoflurane is a halogenated methyl isopropyl ether with the chemical formula C₄H₃F₇O and a molecular weight of 200.05 g/mol. It has a boiling point of 58.6°C and a vapor pressure of 157 mmHg at 20°C.
• Excipient: Water (added in trace quantities as a stabilizer).

Sevorane is presented as a clear, colorless, non-flammable liquid with a mild, pleasant ether-like odor. It is supplied in amber-colored plastic bottles containing 250 mL of liquid. The bottles are available individually or in packs of 6. The filling system uses an integrated adapter designed to fit calibrated vaporizers from all major manufacturers, ensuring safe and accurate transfer of the liquid into the vaporization system.

When used with carbon dioxide absorbents in anesthesia circuits, sevoflurane undergoes degradation to form several compounds, the most notable being Compound A (fluoromethyl-2,2-difluoro-1-[trifluoromethyl]vinyl ether). The formation of Compound A is influenced by the type of absorbent used (barium hydroxide lime produces more than soda lime), the concentration of sevoflurane, the fresh gas flow rate, and the temperature of the absorbent. Modern anesthesia practice typically uses fresh gas flow rates of at least 2 L/min to minimize Compound A exposure, and newer absorbents have been developed that produce less degradation product.